MedTrace Logo

Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease

NCT06392425 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2024-05-01

No results posted yet for this study

Summary

1. To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and Caspase 3 measurement in chronic kidney disease patients
2. Study relationship of serum ADAM 17 and Caspase 3 to stages of chronic kidney disease
3. Compare serum ADAM 17 and Caspase 3 levels in Diabetic Chronic kidney disease patients and Non Diabetic Chronic kidney disease patients

Conditions

  • Chronic Kidney Diseases

Interventions

OTHER

caspase 3 and ADAM 17 biomarkers

Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • samar salah · Assiut University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-26
Primary Completion
2027-03-31
Completion
2027-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06392425 on ClinicalTrials.gov